The World Health Organization (WHO) classification of the myeloid neoplasms

Blood

Volumn 100, Issue 7, 2002, Pages 2292-2302

  Vardiman, James W ^a,b,c,d   Harris, Nancy Lee ^a,b,c   Brunning, Richard D ^a,b,c  

^a UNIVERSITY OF CHICAGO   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; GYRASE INHIBITOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHROMOSOME TRANSLOCATION; CHRONIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CYTOGENETICS; DRUG INDUCED DISEASE; EOSINOPHILIC LEUKEMIA; HEMATOPOIETIC SYSTEM TUMOR; HUMAN; HYPEREOSINOPHILIC SYNDROME; IDIOPATHIC DISEASE; MASTOCYTOSIS; MUTAGENICITY; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; MYELOMONOCYTIC LEUKEMIA; PRIORITY JOURNAL; REVIEW; TUMOR CLASSIFICATION; WORLD HEALTH ORGANIZATION;

EID: 0036786901     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-04-1199     Document Type: Review

References (108)

1. Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.
2. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting - Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3635-3649.
3. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361-1392.
4. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias: French-American-British Cooperative Group. Br J Haematol. 1976;33:451-458.
5. Bennett JM, Catovsky D, Daniel MT, et al. The French-American-British (FAB) Co-operative Group. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189-199.
6. Berlin NI. Diagnosis and classification of the polycythemias. Semin Hematol. 1975;12:339-351.
7. Murphy S, Peterson P, Iland H, et al. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival and leukemia transition by treatment. Semin Hematol. 1997;34:29-39.
8. Sainty D, Liso V, Cantu-Rajnoldi A, et al. A new morphologic classification system for acute promyelocytic leukemia distinguishes cases with underlying PLZF/RARA gene rearrangements. Blood. 2000;96:1287-1296.
9. Geller RB, Zahurak M, Hurwitz CA, et al. Prognostic importance of immunophenotyping in adults with acute myelocytic leukaemia: the significance of the stem-cell glycoprotein CD34 (My10). Br J Haematol. 1990;76:340-347.
10. Braylan RC, Orfao A, Borowitz MJ, Davis BH. Optimal number of reagents required to evaluate hematolymphoid neoplasias: results of an international consensus meeting. Cytometry. 2001;46:23-27.
11. Bain BJ, Barnett D, Linch D, Matutes E, Reilly JT. Revised guideline on immunophenotyping in acute leukemias and chronic lymphoproliferative disorders. Clin Lab Haematol. 2002;24:1-13.
12. Arber DA. Realistic pathologic classification of acute myeloid leukemias. Am J Clin Pathol. 2001;115:552-560.
13. Head DR. Revised classification of acute myeloid leukemia. Leukemia. 1996;10:1826-1831.
14. Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkable distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood. 1997;89:3323-3329.
15. Tallman MS, Andersen JW, Schiffer CA, et al. Alltrans-retinoid acid in acute promyelocytic leukemia. N Engl J Med. 1997;337:1021-1028.
16. Byrd JC, Dodge RK, Carroll A, et al. Patients with the t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol. 1999;17:3767-3775.
17. Head DR. Proposed changes in the definitions of acute myeloid leukemia and myelodysplastic syndrome: are they helpful? Curr Opin Oncol. 2002;14:19-23.
18. Parker JE, Mufti GJ, Rasool F, Mijovic A, Devereux S, Pagliuca A. The role of apoptosis, proliferation and the Bcl-2-related proteins in myelodysplastic syndromes and acute myeloid leukemias secondary to MDS. Blood. 2000;96:3932-3938.
19. Sonneveld P, van Dongen JJM, Hagemeijer A, et al. High expression of the multidrug resistance P-glycoprotein in high-risk myelodysplasia is associated with immature phenotype. Leukemia. 1993;7:963-969.
20. Estey E, Pierce S, Kantarjian H, et al. Treatment of myelodysplastic syndromes with AML-type chemotherapy. Leuk Lymphoma. 1993;11 (suppl 2):59-63.
21. Estey E, Thall P, Beran M, et al. Effects of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood. 1997;90:2969-2977.
22. Bernstein SH, Brunetto VL, Davey FR. Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndromes as defined by French-American-British criteria: a Cancer and Leukemia Group B study. J Clin Oncol. 1996;14:2486-2494.
23. Greenberg P, Cox C, Le Beau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079-2088.
24. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial, Blood. 1998;92:2322-2333.
25. Mrozek K, Heinonen K, Bloomfield CD. Prognostic value of cytogenetic findings in adults with acute myeloid leukemia. Int J Hematol. 2000;72:261-271.
26. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and post-remission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood. 2000;96:4075-4083.
27. Pedersen-Bjergaard J, Andersen MK, Christiansen DH, Nerlov N. Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. Blood. 2002;99:1909-1912.
28. Rowley JD, Olney HJ. International workshop on the relationship of prior therapy to balanced chromosome aberrations in therapy-related leukemia and myelodysplastic syndromes and acute leukemia: overview report. Genes Chromosomes Cancer. 2002;33:331-345.
29. Shurtleff SA, Meyers S, Hiebert SW, et al. Heterogeneity in CBF β/MYH11 fusion messages encoded by the inv(16)(p13q22) and the t(16;16) (p13;q22) in acute myelogenous leukemia. Blood. 1995;85:3695-3703.
30. Mrozek K, Prior TW, Edwards C, et al. Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol. 2001;19:2482-2492.
31. Costello R, Sainty D, Lecine P, et al. Detection of CBFβ/MYH11 fusion transcripts in acute myeloid leukemia: heterogeneity of cytological and molecular characteristics. Leukemia. 1997;11:644-650.
32. Brito-Babapulle F, Catovsky D, Galton DAG. Clinical and laboratory features of de novo acute myeloid leukaemia with trilineage myelodysplasia. Br J Haematol. 1987;66:445-450.
33. Jinnai I, Tomonaga M, Kuriyama K, et al. Dysmegakaryocytopoiesis in acute leukaemias: its predominance in myelomonocytic (M4) leukaemia and implication for poor response to chemotherapy. Br J Haematol. 1987;66:467-472.
34. Goasguen JE, Matsuo T, Cox C, Bennett JM. Evaluation of the dysmyelopoiesis in 336 patients with de novo acute myeloid leukemia: major importance of dysgranulopoiesis for remission and survival. Leukemia. 1992:6:520-525.
35. Gahn B, Haase D, Unterhalt M, et al. De novo AML with dysplastic hematopoiesis: cytogenetic and prognostic significance. Leukemia. 1996;10:946-951.
36. Michels SD, McKenna RW, Arthur DC, Brunning RD. Therapy-related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphologic study of 65 cases. Blood. 1985;65:1364-1372.
37. Le Beau MM, Albain KS, Larson RA, et al. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J Clin Oncol. 1986;4:325-345.
38. Larson RA, Le Beau MM, Vardiman JW, Rowley JD. Myeloid leukemia after hematotoxins. Environ Health Perspect. 1996;104(suppl 6):1303-1307.
39. Karp JE, Sarkodee-Adoo CB. Therapy-related acute leukemia. Clin Lab Med. 2000;20:71-79.
40. Andersen MK, Christiansen DH, Kirchhoff M, Pedersen-Bjergaard J. Duplication or amplification of chromosome band 11q23, including the unrearranged MLL gene, is a recurrent abnormality in therapy-related MDS and AML, and is closely related to mutation of the TP53 gene and to previous therapy with alkylating agents. Genes Chromosomes Cancer. 2001;31:33-41.
41. Ratain MJ, Kaminer LS, Bitran JD, et al. Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung. Blood. 1987;70:1412-1416.
42. Larson RA, Le Beau MM, Ratain MJ, Rowley JD. Balanced translocations involving chromosome bands 11q23 and 21q22 in therapy-related leukemia. Blood. 1982;79:1892-1893.
43. Pedersen-Bjergaard J, Philip P. Balanced translocations involving chromosome bands 11q23 and 21 q22 are highly characteristic of myelodysplasia and leukemia following therapy with cytostatic agents targeting at DNA-topoisomerase II. Blood. 1991;78:1147-1148.
44. Pui CH, Ribeiro R, Hancock ML, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med. 1991;325:1682-1687.
45. Secker-Walker LM, Moorman AV, Bain BJ, Mehta AB. Secondary acute leukemia and myelodysplastic syndrome with 11q23 abnormalities. EU Concerted Action 11q23 Workshop. Leukemia. 1998;12:840-844.
46. Bloomfield C, Archer KJ, Mrozek K, et al. 11q23 balanced chromosome aberrations in treatmentrelated myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosomes Cancer. 2002;33:362-378.
47. Garand R, Duchayne E, Blanchard D, et al. Minimally differentiated erythroleukaemia (AML M6 'variant'): a rare subset of AML distinct from AML M6. Br J Haematol. 1995;90:868-875.
48. Kowal-Vern A, Mazzella FM, Cotelingam JD, Shrit MA, Rector JT, Schumacher HR. Diagnosis and characterization of acute erythroleukemia subsets by determining the percentages of myeloblasts and proerythroblasts in 69 cases. Am J Hematol. 2000;65:5-13.
49. Shichishima T. Minimally differentiated erythroleukemia: recognition of erythroid precursors and progenitors. Intern Med. 2000;39:761-762.
50. Hasserjian RP, Howard H, Wood A, Henry K, Bain B. Acute erythremic myelosis (true erythroleukaemia): a variant of AML FAB-M6. J Clin Pathol. 2001:54:205-209.
51. Muroi K, Tarumoto T, Akioka T, et al. Sialyl-Tn and neuron-specific enolase-positive minimally differentiated erythroleukemia. Intern Med. 2000;39:843-846.
52. DiGuglielmo G. La Malattie Eritremiche ed Eritroleucemlche. Rome: II Pensiero Scientifico Editore; 1962.
53. Sultan C, Sigaux F, Imbert M, Reyes F. Acute myelodysplasia with myelofibrosis: a report of eight cases. Br J Haematol. 1981;49:11-15.
54. Imbert M, Nguyen D, Sultan C. Myelodysplastic syndromes (MDS) and acute myeloid leukemias (AML) with myelofibrosis. Leuk Res. 1992;16:51-54.
55. Fabich DR, Raich PC. Acute myelofibrosis: a report of three cases. Am J Clin Pathol. 1977;67:334-336.
56. Bearman RM, Pangalis GA, Rappaport HR. Acute ("malignant") myelosclerosis. Cancer. 1979;43:279-284.
57. Lewis SM, Szur MB. Malignant myelosclerosis. Br Med J. 1963;ii:472-473.
58. Den Ottolander GJ, Te Velde J, Brederoo P, et al. Megakaryoblastic leukaemia (acute myelofibrosis): a report of three cases. Br J Haematol 1979;42:9-12.
59. Hruban RH, Kuhajda FP, Mann RB. Acute myelofibrosis: immunohistochemical study of four cases and comparison with acute megakaryoblastic leukemia. Am J Clin Pathol. 1987;88:578-588.
60. Coiffier B, Adeleine P, Viala JJ, Byron P. Dysmyelopoietic syndromes: a search for prognostic factors in 193 patients. Cancer. 1983;52:83-90.
61. Vallespi T, Torrabadella M, Julia A, Irriguible D. A study of 101 cases according to the FAB classification. Br J Haematol. 1985;61:83-92.
62. Kerkhofs H, Hermans J, Haak HL, Leeksma C. Utility of the FAB classification for myelodysplastic syndromes: investigation of prognostic factors in 237 cases. Br J Haematol. 1987;65:73-81.
63. Third MIC Cooperative Study Group. Recommendations for a morphologic, immunologic and cytogenetic (MIC) working classification of the primary and therapy related myelodysplastic disorders. Cancer Genet Cytogenet. 1988;32:1-10.
64. Gattermann N, Aul C, Schneider W. Two types of acquired idiopathic sideroblastic anaemia (AISA). Br J Haematol. 1990;74:45-52.
65. Germing U, Gattermann N, Aivado M, Hildebrandt B, Aul C. Two types of acquired idiopathic sideroblastic anaemia (AISA): a time-tested distinction. B J Haematol. 2000;108:724-728.
66. Michels S, Chan W, Jakubowski D, Vogler R. Unclassifiable myelodysplastic syndrome: a study of sixteen cases with a proposal for a new subtype [abstract]. Lab Invest. 1990;62:67.
67. Rosati S, Mick R, Xu F, et al. Refractory cytopenia with multilineage dysplasia: further characterization of an "unclassifiable" myelodysplastic syndrome. Leukemia. 1996;10:20-26.
68. Balduini CL, Guarnone R, Pecci A, Centenara E, Ascari E. Multilineage dysplasia without increased blasts identifies a poor prognosis subset of myelodysplastic syndromes [letter]. Leukemia. 1998;12:1655-1656.
69. Germing U, Gattermann N, Strupp C, Aivado M, Aul C. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res. 2000;24:983-992.
70. Nosslinger T, Raisner R, Koller E, et al. Myelodysplastic syndromes, from French-American-British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution. Blood. 2001;98;2935-2941.
71. Lai F, Godley LA, Joslin J, et al. Transcript map and comparative analysis of the 1.5-Mb commonly deleted segment of human 5q31 in malignant myeloid diseases with a del(5q). Genomics. 2001;71:235-245.
72. Boultwood J, Strickson AJ, Jabs EW, Cheng JF, Fidler C, Wainscoat JS. Physical mapping of the human ATX1 homologue (HAH1) to the critical region of the 5q- syndrome within 5q32, and immediately adjacent to the SPARC gene. Hum Genet. 2000;106:127-129.
73. Van den Berghe H, Cassiman JJ, David G, Fryns JP, Michaux JL, Sokal G. Distinct haematological disorder with deletion of the long arm of no. 5 chromosome. Nature. 1974;251:437-441.
74. Boultwood J, Lewis S, Wainscoat JS. The 5q-syndrome. Blood. 1994;84:3253-3260.
75. Bennett JM, Catovsky D, Daniel MT, et al. The chronic myeloid leukemias: guidelines for distinguishing the chronic granulocytic, atypical chronic myeloid and chronic myelomonocytic leukaemias. Br J Haematol. 1994;87:746-754.
76. Michaux JL, Martiat P. Chronic myelomonocytic leukaemia (CMML): a myelodysplastic or myeloproliferative syndrome? Leuk Lymphoma. 1993;9:35-41.
77. Groupe Francais de Cytogenetique Hematologique. Chronic myelomonocytic leukemia: single entity or heterogeneous disorder? A prospective multicenter study of 100 patients. Cancer Genet Cytogenet. 1991;55:57-65.
78. Germing U, Gattermann N, Minning H, Heyll A, Aul C. Problems in the classification of CMML - dysplastic versus proliferative type. Leuk Res. 1998;22:871-878.
79. Onida F, Kantarjian HM, Smith TL, et al. Prognostic factors in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood. 2002;99:840-849.
80. Fenaux P, Jouet JP, Zandecki M. Chronic and subacute myelomonocytic leukemia in the adult: a report of 60 cases with special reference to prognostic factors. Br J Haematol. 1987;65:101-106.
81. Stornilio AM, Moloney WC, Rosenthal DS, Cox C, Bennett JM. Chronic myelomonocytic leukemia. Leukemia. 1989;4:766-770.
82. Tefferi A, Hoagland HC, Therneau TM, Pierre RV. Chronic myelomonocytic leukemia: natural history and prognostic determinants. Mayo Clin Proc. 1989;64:1246-1254.
83. Shepherd PC, Ganesan TS, Galton DA. Haematological classification of the chronic myeloid leukaemias. Baillieres Clin Haematol. 1987;1:887-906.
84. Hernandez JM, del Canizo MC, Cuneo A, et al. Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia. Ann Oncol. 2000;11:441-444.
85. Niemeyer CM, Fenu S, Hasle H, Mann G, Stary J, van Wering ER. Differentiating juvenile myelomoncytic leukemia from infectious disease. Blood. 1998;91:365-367.
86. Hasle H, Arico M, Basso G, et al. Myelodysplastic syndrome, juvenile myelomonocytic leukemia, and acute myeloid leukemia associated with complete or partial monsomy 7. European Working Group on MDS in Childhood (EWOG-MDS). Leukemia. 1999;13:376-385.
87. Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest. 2000;105:3-7.
88. Cervantes F, Lopez-Guillermo A, Bosch F, Terol MJ, Rozman C, Montserrat E. An assessment of the clinico-hematological criteria for the accelerated phase of chronic myeloid leukemia. Eur J Haematol. 1996;57:286-291.
89. Savage DG, Szydlo RM, Chase A, Apperley JF, Goldman JM. Bone marrow transplantation for chronic myeloid leukaemia: the effects of differing criteria for defining chronic phase on probabilities of survival and relapse. Br J Haematol. 1997;99:30-35.
90. Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M. Chronic myelogenous leukemia: a concise update. Blood. 1993;82:691-703.
91. Brunning RD, McKenna RW. Tumors of the Bone Marrow. Washington, DC: Armed Forces Institute of Pathology; 1994.
92. Cortes JE, Talpaz M, Kantarjian H. Chronic myelogenous leukemia: a review. Am J Med. 1996;100:555-570.
93. Tursz T, Flandrin G, Brouet JC, et al. Coexistence d'un myelome et une leucemie granuleuse en absence de tout traitement: etude de quatre observations [Coexistence of a myeloma and a granulocytic leukemia in the absence of any treatment: study of 4 cases]. Nouv Rev Fr Hematol. 1974;14:693-704.
94. Standen GR, Jasani B, Wagstaff M, et al. Chronic neutrophilic leukemia and multiple myeloma: an association with λ light chain expression. Cancer. 1990;66:162-163.
95. Cehreli C, Undar B, Akkoc N, et al. Coexistence of chronic neutrophilic leukemia with light chain myeloma. Acta Haematol. 1994;91:32-34.
96. Standen GR, Steers FJ, Jones L. Clonality of chronic neutrophilic leukaemia associated with myeloma: analysis using the X-linked probe M 27 β. J Clin Pathol. 1993;46:297-298.
97. Froberg MK, Brunning RD, Dorion P, et al. Demonstration of clonality in neutrophils using FISH in a case of chronic neutrophilic leukemia. Leukemia. 1998;12:623-626.
98. Yanagiasawa K, Ohminami H, Sata M, et al. Neoplastic involvement of granulocytic lineage, not granulocytic-monocytic, monocytic or erythrocytic lineage, in a patient with chronic neutrophilic leukemia. Am J Hematol. 1998;57:221-224.
99. Di Donata C, Croci G, Lazzari S, et al. Chronic neutrophilic leukemia: description of a new case with karyotypic abnormalities. Am J Clin Pathol. 1986;85:369-371.
100. Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine. 1975;54:1-27.
101. Schooley RT, Flaum MA, Gralnick HR, Fauci AS. A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. II. Clinical manifestations. Blood. 1981;58:1021-1026.
102. Bain BJ. Eosinophilic leukaemias and the idiopathic hypereosinophilic syndrome. Br J Haematol. 1996;95:2-9.
103. Ward HP, Block MH. The natural history of agnogenic myeloid metaplasia (AMM) and a critical evaluation of its relationship with the myeloproliferative syndrome. Medicine. 1971;50:357-420.
104. Georgi A, Buesche G, Kreft A. The histopathology of chronic myeloproliferative diseases. Baillieres Clin Haematol. 1998;11:721-749.
105. Thiele J, Kvasnicka HM, Boeltken B, Zankovich R, Diehl V, Fischer R. Initial (prefibrotic) stages of idiopathic (primary) myelofibrosis (IMF) - a clinicopathological study. Leukemia. 1999;13:1741-1748.
106. Boissan M, Feger F, Guillosson JJ, Arock M. c-Kit and c-kit mutations in mastocytosis and other hematological diseases. J Leukoc Biol. 2000;67:135-148.
107. Longley BJ, Metcalfe DD, Tharp M, et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci U S A. 1999;96:1609-1614.
108. Valent P, Horny HP, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res. 2001;25:603-625.